Log in or register to see all Alerts
New HTA Decisions in England
May 2021
Drug name
IMBRUVICA® (ibrutinib)
Company
Janssen
Decision date
//
Therapeutic area
Blood and immune system conditions
Therapeutic sub area
Blood and bone marrow cancers
Decision
Not recommended
Indication
Ibrutinib (Imbruvica) with rituximab for untreated chronic lymphocytic leukaemia.
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for untreated chronic lymphocytic leukaemia because the company did not provide an evidence submission. Janssen has confirmed that it does not intend to make an evidence submission for the appraisal because it considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources for this population. NICE will review this decision if the company decides to make a submission.